Cargando…

RHYTHM-AF: design of an international registry on cardioversion of atrial fibrillation and characteristics of participating centers

BACKGROUND: Atrial fibrillation is a serious public health problem posing a considerable burden to not only patients, but the healthcare environment due to high rates of morbidity, mortality, and medical resource utilization. There are limited data on the variation in treatment practice patterns acr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Crijns, Harry JGM, Bash, Lori D, Chazelle, François, Le Heuzey, Jean-Yves, Lewalter, Thorsten, Lip, Gregory YH, Maggioni, Aldo P, Martín, Alfonso, Ponikowski, Piotr, Rosenqvist, Mårten, Sanders, Prashanthan, Scanavacca, Mauricio, Bernhardt, Alexandra A, Unniachan, Sreevalsa, Phatak, Hemant M, Gitt, Anselm K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3507765/ https://www.ncbi.nlm.nih.gov/pubmed/23031215 http://dx.doi.org/10.1186/1471-2261-12-85

Ejemplares similares

Determinants of left atrium thrombi in scheduled cardioversion: an ENSURE-AF study analysis
por: Merino, Jose L, et al.
Publicado: (2019)

Vernakalant and electrical cardioversion for AF – Safe and effective
por: Simon, Alexander, et al.
Publicado: (2019)

Clinical factors related to successful or unsuccessful cardioversion in the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE‐AF) randomized trial
por: Lip, Gregory Y. H., et al.
Publicado: (2020)

Prediction of Successful Pharmacological Cardioversion in Acute Symptomatic Atrial Fibrillation: The Successful Intravenous Cardioversion for Atrial Fibrillation (SIC-AF) Score
por: Niederdöckl, Jan Daniel, et al.
Publicado: (2022)

Pretreatment with ACE inhibitors improves acute outcome of electrical cardioversion in patients with persistent atrial fibrillation
por: Van Noord, Trudeke, et al.
Publicado: (2005)

Electrical cardioversion in healthy pregnant women: safe yes, but needed?
por: Crijns, H. J. G. M.
Publicado: (2011)

Identifying Patients at High Risk of Left Atrial Appendage Thrombus Before Cardioversion: The CLOTS‐AF Score
por: Segan, Louise, et al.
Publicado: (2023)

Mobile Health for Cardiovascular Disease: The New Frontier for AF Management: Observations from the Huawei Heart Study and mAFA-II Randomised Trial
por: Guo, Yutao, et al.
Publicado: (2020)

Asymptomatic recurrence after AF ablation: Is all lost?
por: Thiyagarajah, Anand, et al.
Publicado: (2017)

Predictors of Adherence to Stroke Prevention in the BALKAN-AF Study: A Machine-Learning Approach
por: Kozieł-Siołkowska, Monika, et al.
Publicado: (2022)

Edoxaban versus warfarin in vitamin K antagonist experienced and naïve patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial
por: Kozieł, Monika, et al.
Publicado: (2020)

Low efficacy of cardioversion of persistent atrial fibrillation with the implantable cardioverter-defibrillator
por: Limantoro, I., et al.
Publicado: (2013)

Electrical cardioversion
por: Sucu, Murat, et al.
Publicado: (2009)

Electrogenic Cardioversion
por: Theodore, Joseph, et al.
Publicado: (2014)

Responsiveness of AF6, a new, short, validated, atrial fibrillation-specific questionnaire—symptomatic benefit of direct current cardioversion
por: Härdén, Marie, et al.
Publicado: (2010)

Investigating the efficacy of chest pressure for direct current cardioversion in atrial fibrillation: a randomised control trial protocol (Pressure-AF)
por: Ferreira, David, et al.
Publicado: (2021)

Gene Expression Signatures of Peripheral Blood Mononuclear Cells during the Early Post-Transplant Period in Patients Developing Cardiac Allograft Vasculopathy
por: Shahzad, Khurram, et al.
Publicado: (2010)

Edoxaban therapy increases treatment satisfaction and reduces utilization of healthcare resources: an analysis from the EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of atrial fibrillation (ENSURE-AF) study
por: Goette, Andreas, et al.
Publicado: (2018)

Clinical Characteristics To Guide The Extent Of Ablation In Paroxysmal AF Patients: Discovering An Old Science
por: Brooks, Anthony G, et al.
Publicado: (2009)

Cardioversion strategy impacts quality of rate control during recurrences of atrial fibrillation
por: Van Der Velden, R, et al.
Publicado: (2023)

Clinical utility of rhythm control by electrical cardioversion to assess the association between self-reported symptoms and rhythm status in patients with persistent atrial fibrillation
por: Hermans, Astrid N.L., et al.
Publicado: (2021)

Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study
por: Friberg, Leif, et al.
Publicado: (2012)

Changes in oral anticoagulation for elective cardioversion: results from a European cardioversion registry
por: Papp, Judit, et al.
Publicado: (2017)

Clinical Features and Prognosis in Patients with Atrial Fibrillation and Prior Stroke: Comparing the Fushimi and Darlington AF Registries
por: Ogawa, Hisashi, et al.
Publicado: (2017)

The COVID-19 Registry in Rhineland-Palatinate in the context of international registry activities documenting COVID-19 outcomes
por: Gitt, Anselm K., et al.
Publicado: (2020)

Corrigendum to: Changes in oral anticoagulation for elective cardioversion: results from a European cardioversion registry
Publicado: (2018)

Use of Direct Oral Anticoagulants Among Patients Undergoing Cardioversion: The Importance of Timing Before Cardioversion
por: Warden, Bruce A., et al.
Publicado: (2018)

A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial
por: Kotecha, Dipak, et al.
Publicado: (2017)

Stroke‐prevention strategies in North American patients with atrial fibrillation: The GLORIA‐AF registry program
por: McIntyre, William F., et al.
Publicado: (2018)

Integrated Care for Atrial Fibrillation Using the ABC Pathway in the Prospective APHRS-AF Registry
por: Bucci, Tommaso, et al.
Publicado: (2023)

Evaluation of the Switch From Amiodarone to Dronedarone in Patients With Atrial Fibrillation: Results of the ARTEMIS AF Studies
por: Naccarelli, Gerald V., et al.
Publicado: (2020)

Gut-microbe derived TMAO and its association with more progressed forms of AF: Results from the AF-RISK study
por: Nguyen, B.O., et al.
Publicado: (2021)

Cardioversion of atrial fibrillation and atrial flutter revisited: current evidence and practical guidance for a common procedure
por: Brandes, Axel, et al.
Publicado: (2020)

COVID-19-Pandemie: Effekte auf die klinische Versorgung von Herz-Kreislauf-Patienten im Frühling 2020
por: Zeymer, Uwe, et al.
Publicado: (2021)

Poor Time in Therapeutic Range Control is Associated with Adverse Clinical Outcomes in Patients with Non-Valvular Atrial Fibrillation: A Report from the Nationwide COOL-AF Registry
por: Krittayaphong, Rungroj, et al.
Publicado: (2020)

Role for machine learning in sex-specific prediction of successful electrical cardioversion in atrial fibrillation?
por: Vinter, Nicklas, et al.
Publicado: (2020)

The Atrial Fibrillation Better Care (ABC) Pathway and Clinical Outcomes in Patients with Atrial Fibrillation: the Prospective Murcia AF Project Phase II Cohort
por: Rivera-Caravaca, José Miguel, et al.
Publicado: (2022)

Electrical energy by electrode placement for cardioversion of atrial fibrillation: a systematic review and meta-analysis
por: Vinter, Nicklas, et al.
Publicado: (2023)

Pharmacological cardioversion for atrial fibrillation and flutter
por: Cordina, J, et al.
Publicado: (2006)

Ibutilide for pharmacological cardioversion of atrial flutter
por: Magnusson, K, et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_atoec92vgbvgiu3m8a2ll85ia4